Compare IDEXX Laboratories, Inc. (IDXX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Realty Income Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Realty Income Corp trades at $54.25 (market cap $51.26B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays a 6.01% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Realty Income Corp for 127 Days on average.
| IDXX | O | |
|---|---|---|
Market Cap | $40.43B | $51.26B |
Volume | 692,164 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $766.68 | $67.56 |
52-Week Low | $504.70 | $53.35 |
Typical Hold Time | 46 Days | 127 Days |
Enterprise Value | $41.32B | $81.88B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Realty Income (O) trades at $54.18, up 1.56% today, but remains in a bearish technical trend with recent earnings misses and a high P/E of 39.54. Revenue grew to $5.75B in 2025, with a net income margin of 21.23%, but rising debt levels and negative cash flow projections for 2026 pose concerns. Analyst sentiment is mixed, with a consensus price target of $64.80, though technical indicators signal caution.
The stock offers a defensive dividend play with consistent payouts, but faces headwinds from rising interest rates and elevated valuation. Upside depends on earnings recovery and debt management, while risks include further technical weakness and macroeconomic pressure on REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
